In-vitro Dissolution: Order and questions [Regulatives / Guidelines]

posted by mittyri  – Russia, 2014-01-22 20:39 (4533 d 07:14 ago) – Posting: # 12230
Views: 10,605

Hi Sireen, Dr_Dan and Helmut!

I would continue this discussion.
According to the chapter 4.2.2
"Similarity of in vitro dissolution should be demonstrated at all conditions within the applied product series, i.e. between additional strengths and the strength(s) (i.e. batch(es)) used for bioequivalence testing."
Do I understand correct the order:
  1. to perform dissolution tests at three different buffers for the BEQ batches of test and reference
  2. to perform dissolution tests at three different buffers for BEQ batch (test) and all additional strengths of test product
    (Linearity of PK is proven)
"It is recommended to use 12 units of the product for each experiment". Why 12? If we obtain results of 6 tablets - isn't it enough for evaluation?
(Our preceding GL states that we could use 6 units only. Now we use EMA GL.)

Is there no need for additional dissolution tests of different strengths of reference product (no need to compare other Reference Batches to the Test Batches)?

What could we do if information is published (not from Originator) about instability of the active substance in one of ph media? Should we check it or refer to the source only?

Kind regards,
Mittyri

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,572 registered users;
163 visitors (0 registered, 163 guests [including 37 identified bots]).
Forum time: 04:53 CEST (Europe/Vienna)

Scientists cannot simply hang their subjectivities
up on a hook outside the laboratory door.    Ruth Bleier

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5